Skip to main content
. 2021 Dec 23;12(1):30. doi: 10.3390/nano12010030

Figure 5.

Figure 5

The antiviral effects of BLG nanoparticle fractions against H1N1 infection in the MDCK cells. MDCK cells were pre-incubated with 100 TCID50 H1N1 for 2 h at 34 °C and treated with the BLG-NPs fractions at the concentration of 0.05–0.4 mg/mL at 34 °C. MDCK cell viability of cells was evaluated by MTT assay. Values are expressed as the mean ± SD (n = 4). * p < 0.05, ** p < 0.01 compared to the virus group using the two-way ANOVA followed by Dunnett’s multiple comparisons test.